Get the most recent information regarding the Novartis Campus in Basel. This page features updates on campus accessibility, architectural programs, and general site announcements to help you stay informed before your visit.
Discover how Novartis is shaping the future of medicine through advancements in oncology, neuroscience, and immunology. This update highlights the strategic focus of R&D leaders on causal biology, technological platforms, and the commitment to delivering transformative patient outcomes.
Novartis has reported positive biomarker results from its Phase I/II clinical trial of delpacibart braxlosiran (del-brax), an investigational treatment for FSHD. This progress represents a critical step in the development of potential disease-modifying therapies for this rare neuromuscular condition. The company is now working toward Phase III trials to further evaluate the efficacy and safety of this new therapeutic approach.
Novartis is set to share significant clinical findings at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026. The presentation will feature results from the Phase III RemIND trial and extension data for Rhapsido, focusing on its impact across chronic inducible and spontaneous urticaria as well as food allergy research.
Novartis has announced 144-week results from the ASC4FIRST clinical trial, showing sustained efficacy and improved safety profiles for Scemblix in newly diagnosed CML patients. The data highlights significant molecular response rates compared to standard tyrosine kinase inhibitors, marking a step forward in long-term treatment outcomes.
Discover how Novartis is shaping the future of medicine through advancements in oncology, neuroscience, and immunology. This update highlights the strategic focus of R&D leaders on causal biology, technological platforms, and the commitment to delivering transformative patient outcomes.
Novartis is set to share significant clinical findings at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026. The presentation will feature results from the Phase III RemIND trial and extension data for Rhapsido, focusing on its impact across chronic inducible and spontaneous urticaria as well as food allergy research.
Discover how Novartis is shaping the future of medicine through advancements in oncology, neuroscience, and immunology. This update highlights the strategic focus of R&D leaders on causal biology, technological platforms, and the commitment to delivering transformative patient outcomes.
Novartis has announced 144-week results from the ASC4FIRST clinical trial, showing sustained efficacy and improved safety profiles for Scemblix in newly diagnosed CML patients. The data highlights significant molecular response rates compared to standard tyrosine kinase inhibitors, marking a step forward in long-term treatment outcomes.
Locate prestigious art institutions and heritage sites easily.
Streamline your search for cultural landmarks in Basel. Identify historical archives, fine art hubs, and scientific collections tailored to your specific curiosity. Access essential details for every venue to coordinate your upcoming visit.
